Syndax Names Aaron Ondrey to Succeed Retiring CFO

Company Syndax Pharmaceuticals Event Type CFO transition Modality Not applicable (corporate) Asset Revumenib; axatilimab Target Menin; CSF1R Disease Area Acute leukemia; chronic GVHD Summary Previously missed November 2 leadership change: Syndax appointed Aaron A. Ondrey chief financial officer effective November 9, succeeding Keith A. Goldan,…